id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S6624 R18202 |
Burja (Phenobarbital) (Controls unexposed, disease free), 2006 | Intracranial hemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, disease free excluded | Adjustment: No |
37.36 [0.68;2061.38] C excluded (control group) |
0/1 5/211 | 5 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6620 R18182 |
Burja (Phenobarbital) (Controls unexposed, sick), 2006 | Intracranial hemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 11.80 [0.19;731.60] C | 0/1 2/32 | 2 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6686 R18629 |
D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 | Periventricular haemorrhage (germinal layer) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
17.57 [0.30;1024.08] C excluded (control group) |
0/4 0/62 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6694 R18790 |
D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 | Periventricular haemorrhage (germinal layer) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.14 [0.03;131.94] C | 0/4 0/8 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 5.02 [0.27;92.72] | 2 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed, sick; 2: Phenobarbital) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6686, 6624